Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

QNRX

Quoin Pharmaceuticals Ltd ADR

Apr 29 • 04:00PM ET

5.93

+0.48 8.81 %

Healthcare • Biotechnology • USA • Nano • NASD

Apr 28, 8:35 AMQuoin Pharmaceuticals to start QRX009 trials in Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex later this year

Peers: ASND RDHL MDGL XENE TGTX CRIS VYGR ADAP MREO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-460.50	Insider Own	-	Shs Outstand	1.50M	Perf Week	3.31%
Market Cap	8.89M	Forward P/E	-	EPS next Y	-4.05	Insider Trans	-	Shs Float	-	Perf Month	-5.57%
Enterprise Value	-9.85M	PEG	-	EPS next Q	-1.99	Inst Own	56.07%	Short Float	-	Perf Quarter	-34.84%
Income	-15.91M	P/S	-	EPS this Y	65.74%	Inst Trans	40.62%	Short Ratio	0.81	Perf Half Y	-55.08%
Sales	0.00M	P/B	0.68	EPS next Y	20.02%	ROA	-88.14%	Short Interest	0.08M	Perf YTD	-58.91%
Book/sh	8.76	P/C	0.47	EPS next 5Y	59.89%	ROE	-142.53%	52W High	41.80 -85.81%	Perf Year	-9.88%
Cash/sh	12.49	P/FCF	-	EPS past 3/5Y	-631.16% -180.43%	ROIC	-121.27%	52W Low	5.20 14.04%	Perf 3Y	-97.18%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.49% 10.53%	Perf 5Y	-99.99%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-464.26%	Oper. Margin	-	ATR (14)	0.63	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.61	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	42.76	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.61	EPS Q/Q	76.62%	SMA20	-2.40%	Beta	1.53	Target Price	29.67
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-19.56%	Rel Volume	0.25	Prev Close	5.45
Employees	4	LT Debt/Eq	0.00	Earnings	Mar 26 BMO	SMA200	-39.60%	Avg Volume	99.67K	Price	5.93
IPO	Jul 29, 2016	Option/Short	No / Yes	EPS/Sales Surpr.	56.72% -	Trades		Volume	24,616	Change	8.81%

Apr-28-26 12:02PM	CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs (GlobeNewswire)
08:30AM	Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs (GlobeNewswire)
Mar-26-26 08:30AM	Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire) -18.39%
Mar-25-26 08:30AM	Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome (GlobeNewswire) +15.88%
Mar-19-26 08:30AM	Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026 (GlobeNewswire) +5.36%
08:30AM	Loading…
Mar-11-26 08:30AM	Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome (GlobeNewswire)
Feb-26-26 08:30AM	NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome (GlobeNewswire)
Jan-27-26 08:30AM	Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome (GlobeNewswire)
Jan-20-26 08:30AM	Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome (GlobeNewswire)
Nov-11-25 08:30AM	Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies (GlobeNewswire) +41.40%
Nov-06-25 08:30AM	Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results (GlobeNewswire) -11.19%
Oct-30-25 08:30AM	Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025 (GlobeNewswire) -7.15%
Oct-28-25 08:30AM	Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month 'Whole Body' Data Update from Ongoing Study (GlobeNewswire)
Oct-21-25 08:30AM	Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome (GlobeNewswire)
Oct-10-25 09:24AM	Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million (GlobeNewswire) +151.23%
08:30AM	Loading…
Sep-09-25 08:30AM	Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome (GlobeNewswire)
Aug-21-25 08:30AM	Quoin Pharmaceuticals' NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome (GlobeNewswire)
Aug-18-25 08:30AM	Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy (GlobeNewswire)
Aug-12-25 08:30AM	Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton (GlobeNewswire)
Aug-07-25 08:30AM	Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update (GlobeNewswire) -6.24%
Jul-31-25 08:30AM	Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025 (GlobeNewswire) -12.36%
Jul-29-25 08:30AM	Quoin Pharmaceuticals Provides Product Portfolio Update (GlobeNewswire)
Jun-26-25 08:30AM	Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases (GlobeNewswire)
Jun-24-25 08:30AM	Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome (GlobeNewswire)
May-22-25 07:30AM	Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study (GlobeNewswire)
May-20-25 07:30AM	Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome (GlobeNewswire) +6.01%
May-14-25 07:30AM	Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study (GlobeNewswire) +20.28%
May-13-25 08:00AM	Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results (GlobeNewswire)
May-06-25 08:00AM	Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025 (GlobeNewswire)
Apr-30-25 07:30AM	Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire)
07:30AM	Loading…
Apr-10-25 07:30AM	Quoin Pharmaceuticals Releases Second Episode of its Living with Netherton Series, as part of its ongoing NETHERTON NOW awareness campaign (GlobeNewswire) -20.32%
Apr-02-25 07:30AM	Quoin Pharmaceuticals Announces Additional Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient (GlobeNewswire) +38.23%
Mar-25-25 07:30AM	Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases (GlobeNewswire)
Mar-13-25 07:30AM	Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
Mar-06-25 08:00AM	Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025 (GlobeNewswire) -7.35%
Mar-04-25 07:30AM	Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications (GlobeNewswire)
Feb-27-25 07:30AM	Quoin Pharmaceuticals Announces Highly Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study (GlobeNewswire) +15.40%
Feb-25-25 07:30AM	Quoin Pharmaceuticals Launches First Episode of "NETHERTON NOW" Video Series to Raise Awareness for Netherton Syndrome (GlobeNewswire)
Feb-04-25 07:30AM	Quoin Pharmaceuticals Launches 'NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure (GlobeNewswire)
Jan-23-25 08:30AM	Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome (GlobeNewswire) -30.22%
05:30AM	Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies (ACCESSWIRE)
Jan-14-25 08:30AM	Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study (GlobeNewswire)
Jan-07-25 02:29PM	PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials (GlobeNewswire)
Jan-06-25 08:30AM	Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study (GlobeNewswire)
Dec-20-24 09:20AM	Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering (GlobeNewswire) -12.03%
Dec-19-24 08:00AM	Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study (GlobeNewswire) +14.99%
Dec-18-24 08:18AM	Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies (GlobeNewswire) -6.65%
Nov-07-24 08:00AM	Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 08:00AM	Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient (GlobeNewswire)
Oct-31-24 04:05PM	Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024 (GlobeNewswire) -7.78%
Oct-22-24 08:00AM	Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome (GlobeNewswire) -13.03%
Sep-09-24 08:30AM	Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO (GlobeNewswire) +24.71%
Aug-08-24 08:30AM	Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results (GlobeNewswire) -7.17%
Aug-06-24 05:00AM	Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome (GlobeNewswire)
Aug-01-24 04:10PM	Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (GlobeNewswire)
Jun-27-24 08:00AM	Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome (GlobeNewswire)
Jun-25-24 04:05PM	Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference (GlobeNewswire)
Jun-12-24 08:00AM	Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland (GlobeNewswire)
May-09-24 08:30AM	Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results (GlobeNewswire)
May-02-24 04:10PM	Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire) +6.34%
Mar-15-24 10:52AM	Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 04:05PM	Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results (GlobeNewswire) -13.79%
Mar-07-24 04:05PM	Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET (GlobeNewswire) -8.47%
Mar-05-24 08:34AM	Why Is Quoin Pharmaceuticals (QNRX) Stock Down 50% Today? (InvestorPlace) -48.28%
08:00AM	Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering (GlobeNewswire)
Mar-04-24 08:00AM	Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies (GlobeNewswire)
Feb-14-24 09:00AM	Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome (ACCESSWIRE)
Feb-08-24 08:00AM	Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product (GlobeNewswire)
Dec-13-23 08:30AM	Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome (GlobeNewswire)
Nov-10-23 12:19PM	Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 05:46PM	Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results (GlobeNewswire) -8.26%
Nov-03-23 08:41AM	Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET (GlobeNewswire)
Oct-24-23 09:32AM	REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome (GlobeNewswire) +8.04%
08:28AM	Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome (GlobeNewswire)
Oct-02-23 12:25PM	QNRX: Positive Early Clinical Data, Moving QRX003 Through Multiple Trials (Zacks)
Aug-09-23 08:30AM	Quoin Pharmaceuticals' Commitment to Delivering Treatment for Netherton Syndrome Patients and Creating Value for Shareholders (NewMediaWire)
Aug-02-23 04:45PM	Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results (GlobeNewswire) -10.67% +6.26%
Jul-27-23 08:00AM	Quoin Pharmaceuticals Announces Second Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday August 3rd at 8:30 am ET (GlobeNewswire)
May-24-23 08:15AM	Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial (GlobeNewswire)
May-08-23 05:00PM	Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results (GlobeNewswire) +14.90% -14.23%
May-02-23 08:30AM	Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET (GlobeNewswire)
Mar-22-23 09:13AM	QNRX: Patients Dosed in Both Concurrent Studies; Potentially Adding New Assets to Product Portfolio (Zacks Small Cap Research) +5.92%
Mar-21-23 08:30AM	Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial (GlobeNewswire)
Mar-11-23 02:59AM	Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-08-23 05:08PM	Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -7.83%
Mar-02-23 04:05PM	Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET (GlobeNewswire)
Mar-01-23 08:30AM	A Pivotal Year Ahead for Quoin Pharmaceuticals (NewMediaWire)
Feb-22-23 08:39AM	Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering (GlobeNewswire) -47.90%
Dec-13-22 08:30AM	Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome (GlobeNewswire)
Dec-05-22 11:15AM	QNRX: Moving QRX003 Forward in Concurrent Studies (Zacks Small Cap Research)
Nov-10-22 08:30AM	Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2022 Financial Results (GlobeNewswire) +17.07%
Nov-03-22 07:00AM	Quoin Pharmaceuticals Announces Updated Timing of Third Quarter 2022 Corporate Update Conference Call to be held on Thursday November 10th (GlobeNewswire)
Nov-01-22 08:30AM	Quoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10th (GlobeNewswire)
Oct-18-22 08:30AM	Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients (GlobeNewswire) +44.44%
Sep-13-22 08:30AM	Quoin Pharmaceuticals Establishes Patient Specific Website for Ongoing Netherton Syndrome Clinical Study (GlobeNewswire) -7.75%
Aug-23-22 01:43PM	QNRX: Enhanced Financial Flexibility to Move QRX003 & Other Assets Forward (Zacks Small Cap Research) -9.13%
Aug-18-22 07:00AM	Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2022 Financial Results (GlobeNewswire) -10.40%
Aug-11-22 04:30PM	Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th (GlobeNewswire)
Aug-09-22 04:23PM	Quoin Pharmaceuticals Announces Closing of $16.8 Million Public Offering (GlobeNewswire) -8.77%
Aug-05-22 09:28AM	Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering (GlobeNewswire) -62.38%

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LANGER DENNIS	Director	Oct 14 '25	Buy	8.49	15,152	128,640	15,153	Oct 15 05:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

QNRX

Quoin Pharmaceuticals Ltd ADR

Upgrade your Finviz experience